Novo Nordisk stock news
On September 28, 2026, Novo Nordisk entered into an exclusive global license agreement with Sweden--based drug delivery company Nanexa AB valued at up to €1.165 billion ($1.33 billion). Under the agreement, Novo Nordisk secures access to Nanexa's proprietary PharmaShell technology to develop long--acting injectable formulations in the cardiometabolic area. The deal structure includes up to €615 million ($701 million) in upfront and development milestone payments, alongside commercial sales milestones and low single--digit royalties, supporting Novo Nordisk's strategic push to bolster its pipeline and counter intensifying market competition.